Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

According to APO Research, The global Benign Prostatic Hyperplasia (BPH) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Benign Prostatic Hyperplasia (BPH) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA and Mylan, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Benign Prostatic Hyperplasia (BPH) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Benign Prostatic Hyperplasia (BPH) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Benign Prostatic Hyperplasia (BPH) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Benign Prostatic Hyperplasia (BPH) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Benign Prostatic Hyperplasia (BPH) Drugs sales, projected growth trends, production technology, application and end-user industry.


Benign Prostatic Hyperplasia (BPH) Drugs Segment by Company

Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals
Drugstores
Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Benign Prostatic Hyperplasia (BPH) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Benign Prostatic Hyperplasia (BPH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Benign Prostatic Hyperplasia (BPH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
2.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
2.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
3 Benign Prostatic Hyperplasia (BPH) Drugs Market by Manufacturers
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2020-2025)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers, Product Type & Application
3.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Benign Prostatic Hyperplasia (BPH) Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Benign Prostatic Hyperplasia (BPH) Drugs Tier 1, Tier 2, and Tier 3
4 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
4.1 Benign Prostatic Hyperplasia (BPH) Drugs Type Introduction
4.1.1 Alpha-Blocker
4.1.2 Phosphodiesterase Type-5 Inhibitors
4.1.3 Others
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2020-2031)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2020-2031)
4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type
4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2020-2031)
4.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2020-2031)
5 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
5.1 Benign Prostatic Hyperplasia (BPH) Drugs Application Introduction
5.1.1 Hospitals
5.1.2 Drugstores
5.1.3 Others
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2020-2031)
5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2020-2031)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application
5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2020-2031)
5.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2020-2031)
6 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region
6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2031)
6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2020-2025)
6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
7.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region
7.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2020-2025)
7.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2026-2031)
7.1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2020-2031)
7.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2020-2031)
7.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Eli Lilly
8.1.1 Eli Lilly Comapny Information
8.1.2 Eli Lilly Business Overview
8.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.1.5 Eli Lilly Recent Developments
8.2 GlaxoSmithKline
8.2.1 GlaxoSmithKline Comapny Information
8.2.2 GlaxoSmithKline Business Overview
8.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.2.5 GlaxoSmithKline Recent Developments
8.3 Astellas Pharma
8.3.1 Astellas Pharma Comapny Information
8.3.2 Astellas Pharma Business Overview
8.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.3.5 Astellas Pharma Recent Developments
8.4 Sanofi
8.4.1 Sanofi Comapny Information
8.4.2 Sanofi Business Overview
8.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.4.5 Sanofi Recent Developments
8.5 Pfizer
8.5.1 Pfizer Comapny Information
8.5.2 Pfizer Business Overview
8.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.5.5 Pfizer Recent Developments
8.6 Abbott
8.6.1 Abbott Comapny Information
8.6.2 Abbott Business Overview
8.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.6.5 Abbott Recent Developments
8.7 Allergan
8.7.1 Allergan Comapny Information
8.7.2 Allergan Business Overview
8.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.7.5 Allergan Recent Developments
8.8 TEVA
8.8.1 TEVA Comapny Information
8.8.2 TEVA Business Overview
8.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.8.5 TEVA Recent Developments
8.9 Mylan
8.9.1 Mylan Comapny Information
8.9.2 Mylan Business Overview
8.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.9.5 Mylan Recent Developments
8.10 Novartis
8.10.1 Novartis Comapny Information
8.10.2 Novartis Business Overview
8.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.10.5 Novartis Recent Developments
8.11 Merck
8.11.1 Merck Comapny Information
8.11.2 Merck Business Overview
8.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
8.11.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
9.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process
9.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
9.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings